Dr. Reddy’s Launches Rituxan Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian company plans to market Reditux in India at half the cost of Genentech/Biogen Idec’s Rituxan (rituximab).
You may also be interested in...
Indian Companies Ramping Up For Follow-On Biologics
Indian pharma firms are expected to be active in filing for biosimilar approvals, Ranbaxy exec tells “The Pink Sheet” DAILY
Ranbaxy’s First Biosimilar Target Will Be Amgen’s Neupogen
Ranbaxy is partnered with another Indian drug maker, Zenotech, in its foray into biosimilar development.
Rituxan Adds Third NHL Indication In 2006
The Genentech/Biogen Idec oncologic, first approved in 1997, is now also approved for first-line with CVP and ongoing treatment of stable disease.